The abstract is read at the publisher; the summary is JClub's.
Ulixertinib showed no objective responses (ORR 0%) in 34 pancancer patients with BRAF fusions or non-V600E/non-V600K BRAF mutations.
- Why it matters: BRAF fusions and non-V600 BRAF mutations can depend on the RAF-MEK-ERK pathway, but clinical activity of ERK1/2 inhibition in this setting is uncertain.
- What they did: In a single-arm NCI-MATCH ECOG-ACRIN trial subprotocol (Z1L), patients received ulixertinib 600 mg twice daily continuously in 28-day cycles, with ORR as the primary endpoint.
- The result: Across centrally confirmed cases, stable disease was the best response in 7 of 26, with median PFS 1.7 months and 6-month PFS 5%, and median OS 3.5 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.